高出血风险患者缩短或标准双联抗血小板治疗的性别差异:随机临床试验预设二次分析
该研究为MASTER DAPT试验的预设亚组分析,纳入4579例高出血风险PCI患者,随机分为缩短DAPT组或标准DAPT组。结果显示缩短DAPT在男女中NACE率相当,但MACCE存在性别异质性,女性有获益趋势,男性无获益;MCB无显著交互作用。
要点
- 缩短DAPT在男女中NACE率相当,交互作用P=0.65。
- MCB无显著性别交互作用,男性获益相对更大。
核心结论
- 高出血风险女性与男性相比,缺血和出血事件发生率相似。
- 缩短DAPT相比标准DAPT可能使女性尤其获益,因事件数值上更低。
研究设计与样本
- MASTER DAPT试验的预设亚组比较效果分析,多中心、随机、开放标签临床试验。
- 在30个国家140个中心进行,2017年2月28日至2019年12月5日。
- 共4579例高出血风险患者,PCI后1个月随机分为缩短DAPT组或标准DAPT组。
主要发现
- 女性1408例(30.7%),男性3171例(69.3%),平均年龄76.0岁(SD 8.7)。
- 缩短DAPT的NACE率在男性HR 0.97(95%CI 0.75-1.24),女性HR 0.87(95%CI 0.60-1.26),交互P=0.65。
临床怎么用
- 高出血风险PCI患者中,缩短DAPT可考虑用于女性,因MACCE有获益趋势。
- 男性患者缩短DAPT的MACCE风险需权衡,尽管出血获益更明显。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). OBJECTIVES: To evaluate the association of sex with the comparative effectiveness of abbreviated vs standard DAPT in patients with HBR. DESIGN, SETTING, AND PATIENTS: This prespecified subgroup comparative effectiveness analysis followed the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated vs Standard DAPT Regimen (MASTER DAPT) trial, a multicenter, randomized, open-label clinical trial conducted at 140 sites in 30 countries and performed from February 28, 2017, to December 5, 2019. A total of 4579 patients with HBR were randomized at 1 month after PCI to abbreviated or standard DAPT. Data were analyzed from July 1 to October 31, 2022. INTERVENTIONS: Abbreviated (immediate DAPT discontinuation, followed by single APT for ≥6 months) or standard (DAPT for ≥2 additional months, followed by single APT for 11 months) treatment groups. MAIN OUTCOMES AND MEASURES: One-year net adverse clinical events (NACEs) (a composite of death due to any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (MACCEs) (a composite of death due to any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding (MCB). RESULTS: Of the 4579 patients included in the analysis, 1408 (30.7%) were women and 3171 (69.3%) were men (mean [SD] age, 76.0 [8.7] years). Ischemic and bleeding events were similar between sexes. Abbreviated DAPT was associated with comparable NACE rates in men (hazard ratio [HR], 0.97 [95% CI, 0.75-1.24]) and women (HR, 0.87 [95% CI, 0.60-1.26]; P = .65 for interaction). There was evidence of heterogeneity of treatment effect by sex for MACCEs, with a trend toward benefit in women (HR, 0.68 [95% CI, 0.44-1.05]) but not in men (HR, 1.17 [95% CI, 0.88-1.55]; P = .04 for interaction). There was no significant interaction for MCB across sex, although the benefit with abbreviated DAPT was relatively greater in men (HR, 0.65 [95% CI, 0.50-0.84]) than in women (HR, 0.77 [95% CI, 0.53-1.12]; P = .46 for interaction). Results remained consistent in patients with acute coronary syndrome and/or complex PCI. CONCLUSIONS AND RELEVANCE: These findings suggest that women with HBR did not experience higher rates of ischemic or bleeding events compared with men and may derive particular benefit from abbreviated compared with standard DAPT owing to these numerically lower rates of events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03023020.
引用
- Landi A, Alasnag M, Heg D, et al. Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2024. PMID: 37991745. doi:10.1001/jamacardio.2023.4316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。